Apyx Medical Corporation APYX
Set alert
As of Nov 2, 1:41 PM ET
- YTD
- -24.57%
- 1 year
- -12.87%
- Open
- 2.58
- Prev close
- 2.60
- Mkt cap
- 111.21M
- Vol
- 76.59K
- Avg vol
- 142.47K
- EPS
- -0.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.56
- High
- 2.80
- Forward P/E
- -3.39
- Beta
- 1.21
- Short ratio
- 5.49
- Inst. own
- 40.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.41
- 200-d avg
- 1.39
- 1y target
- 2.83
Discussion (3)
Sign in to join the discussion
VICKY HANUKA APYX 3 years ago #1Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
$CNDT is making billions in revenue with only a 1.5 billion market cap. The is set to fly ??? https://www.aviseanalytics.com/should-conduent-be-a-part-of-your-investment-portfolio/
$ATOS
Atos Announces 10 New Supercomputer Entries in the TOP500 Listing ?